Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.61 USD
Change Today +0.0044 / 0.72%
Volume 1.2M
STEM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Key Developments

StemCells Seeks Acquisitions

StemCells Inc. (NasdaqCM:STEM) is seeking acquisitions. StemCells has filed a Follow-on Equity Offering, the net proceeds of which will be used for general corporate purposes, including working capital, capital expenditures and research and development, as well as acquisitions and other strategic purposes.

StemCells, Inc. Completes Enrollment of First Cohort in Phase II Pathway Study for Cervical Spinal Cord Injury

StemCells Inc. announced that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the Company's proprietary HuCNS-SC (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI).

StemCells Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 03:40 PM

StemCells Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 03:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Martin M. McGlynn, Chief Executive Officer, Chief Executive Officer of Stemcells California Inc, President of Stemcells California Inc, Director and Member of Strategic Transactions Committee.

StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer

StemCells Inc. announced that Ian Massey has joined its executive team as President and Chief Operating Officer, effective March, March 23, 2015. In this new role, Dr. Massey has direct responsibility for all aspects of the company's research and development, manufacturing, regulatory affairs, and quality assurance activities. He reports to Martin McGlynn, the company's Chief Executive Officer. Most recently, he was the COO and President of U.S. Operations of Biotie Therapies Corporation.

StemCells Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Impairment of Goodwill and Other Intangible Assets for the Fourth Quarter Ended December 31, 2014; Plans to Initiate Controlled Proof-Of-Concept Phase II Study in Geographic Atrophy of Dry Age Related Macular Degeneration

StemCells Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, the company reported a net loss of $10,108,000 from continuing operations and net loss of $10,249,000 or $0.15 per basic and diluted share, in comparison, for the fourth quarter of 2013, the company reported a net loss of $6,848,000 from continuing operations and net loss of $6,963,000, or $0.13 per basic and diluted share. Non-GAAP net loss was $9,330,000 or $0.14 per basic and diluted share, in comparison, for the fourth quarter of 2013, the company reported a non-GAAP net loss of $8,887,000 or $0.16 per basic and diluted share. Total revenue from continuing operations was $883,000, compared to $45,000 in the same period of 2013. Revenue from continuing operations is primarily from royalties and milestone payments received under various licensing agreements. Loss from operations was $9.729 million compared to $9.296 million a year ago. For the full year 2014, the company reported a net loss of $32,741,000, or $0.53 per share, compared with a net loss of $26,439,000, or $0.61 per basic and diluted share, for 2013. Non-GAAP net loss was $29,381,000 or $0.48 per basic and diluted share, comparison, for the fourth quarter of 2013; the company reported a non-GAAP net loss of $26,024,000 or $0.60 per basic and diluted share. The approximately $3,400,000 increase is primarily associated with increased levels of clinical activity. Total revenue from continuing operations was $1,012,000 compared to $172,000 for 2013. The increase in 2014 was primarily attributable to a milestone payment of approximately $500,000 received under a licensing agreement with ReNeuron Ltd. and a licensing fee of approximately $400,000 in connection with divestiture of the SC Proven business entered into with Takara Bio Inc. Cash used in operations totaled $27,352,000, compared to $23,322,000 in 2013. Loss from operations was $30.910 million compared to $28.093 million a year ago. The company reported wrote-off approximately $2,440,000 in goodwill and other intangible assets related to its discontinued SC Proven business and other technology not related to therapeutic product development programs for the fourth quarter ended December 31, 2014. The company announced that it will shortly initiate a controlled proof-of-concept Phase II study in geographic atrophy of dry age related macular degeneration, advanced form of the disease and a cause of blindness in the elderly.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $0.61 USD +0.0044

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.16 USD -0.04
Bioheart Inc $0.0068 USD 0.00
Biorestorative Therapies Inc $0.37 USD 0.00
Cytori Therapeutics Inc $0.87 USD -0.0098
Nuo Therapeutics Inc $0.22 USD 0.00
View Industry Companies
 

Industry Analysis

STEM

Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.